EMA Authorised: Tobi Podhaler (tobramycin) — Viatris Healthcare Limited

View source ↗

Summary

EMA authorised Tobi Podhaler (tobramycin) for cystic fibrosis and respiratory tract infections; the marketing authorisation holder is Viatris Healthcare Limited…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Respiratory Tract Infections

Drugs mentioned

• TOBI Podhaler (tobramycin inhalation powder)

Snippet

Status: Authorised. Therapeutic area: Cystic Fibrosis;Respiratory Tract Infections. MAH: Viatris Healthcare Limited. Decision date: 11/12/2025